Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

被引：24
|
作者：
Laroni, A. [1 ]
Brogi, D. [1 ]
Milesi, V. [1 ]
Abate, L. [1 ]
Uccelli, A. [1 ]
Mancardi, G. L. [1 ]
机构：
[1] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, I-16132 Genoa, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2013年 / 19卷 / 09期
关键词：
MULTIPLE-SCLEROSIS;
D O I：
10.1177/1352458512468498
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1236 / 1237
页数：2
相关论文
共 50 条
  • [21] Follow-up of multiple sclerosis (MS) patients after natalizumab interruption. Clinical and MRI findings. Switching to treatment with fingolimod
    Evangelopoulos, M. E.
    Andreadou, E.
    Deligianni, C.
    Saltogiannis, G.
    Chasalevris, I.
    Chaina, V.
    Kilidireas, C.
    JOURNAL OF NEUROLOGY, 2013, 260 : S68 - S68
  • [22] Identification of men with the highest risk of early disease recurrence after radical prostatectomy
    Sundi, Debasish
    Wang, Vinson
    Pierorazio, Phillip M.
    Han, Misop
    Partin, Alan W.
    Tran, Phuoc T.
    Ross, Ashley E.
    Bivalacqua, Trinity J.
    PROSTATE, 2014, 74 (06): : 628 - 636
  • [23] Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk Reply
    Alping, Peter
    Frisell, Thomas
    Svenningsson, Anders
    Piehl, Fredrik
    ANNALS OF NEUROLOGY, 2016, 80 (05) : 791 - 792
  • [24] Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis
    Naegelin, Y.
    Rasenack, M.
    Andelova, M.
    Von Felten, S.
    Fischer-Barnicol, B.
    Amann, M.
    Mehling, M.
    Kappos, L.
    Sprenger, T.
    Derfuss, T.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 25 : 14 - 20
  • [25] Statins may decrease cardiovascular disease risk by reducing inflammation
    Bonn, D
    LANCET, 1999, 354 (9175): : 311 - 311
  • [26] Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment
    Pantazou, Vasiliki
    Pot, Caroline
    Du Pasquier, Renaud
    Le Goff, Geraldine
    Theaudin, Marie
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 51
  • [27] Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma
    Kim, Seo Ki
    Woo, Jung-Woo
    Lee, Jun Ho
    Park, Inhye
    Choe, Jun-Ho
    Kim, Jung-Han
    Kim, Jee Soo
    ENDOCRINE-RELATED CANCER, 2016, 23 (05) : 367 - 376
  • [28] CEREBRAL MICROBLEEDS ARE THE RISK FACTOR FOR EARLY STROKE RECURRENCE AFTER SMALL VESSEL DISEASE
    Terasawa, Y.
    Shimomura, R.
    Nakamichi, A.
    Sato, K.
    Himeno, T.
    Takamatsu, K.
    Shimoe, Y.
    Kohriyama, T.
    INTERNATIONAL JOURNAL OF STROKE, 2020, 15 (1_SUPPL) : 572 - 572
  • [29] Rebound of disease activity after discontinuation of natalizumab or fingolimod can be successfully treated with autologous haematopoietic stem cell transplantation
    Curro, D.
    Gualandi, F.
    Cavalla, P.
    Capello, E.
    Uccelli, A.
    Mattioda, A.
    Boffa, G.
    Mancardi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 621 - 622
  • [30] Early switch to fingolimod to achieve 'No Evidence of Disease Activity' (NEDA) over 7 years in the TRANSFORMS Study
    Hartung, H-P.
    Cohen, J. A.
    Khatri, B.
    Silva, D.
    Meier, D. Piani
    Ritter, S.
    Tomic, D.
    Barkhof, F.
    Kappos, L.
    Montalban, X.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 496 - 496
12345